Search clinical trials for: Doxorubicin Hydrochloride Liposome Injection

Total 19470 results

SCRI Development Innovations, LLC
Seagen Inc.

Recruiting

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Breast Cancer

United States
Shanghai Pudong Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study (easy laugh)

Breast Cancer

China
Baxter Healthcare Corporation

Not yet recruiting

Doxil/Caelyx BE Study

Multiple Myeloma | Ovarian Cancer | Metastatic Breast Cancer | AIDS-related Kaposi Sarcoma
Sun Yat-sen University
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Doxorubicin Hydrochloride Liposome Combined With Irinotecan Versus VIT Regimen in the Treatment of Pediatric Rhabdomyosarcoma

Rhabdomyosarcoma, Child
Fudan University

Recruiting

Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo

Advanced Malignant Tumors

China
Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Hunan Cancer Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University and other collaborators

Recruiting

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients

Breast Cancer | Ovarian Cancer

China
Fudan University

Recruiting

R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse

Diffuse Large B-cell Lymphoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

Breast Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial

Breast Cancer | Hormone-receptor Positive Breast Cancer

China
Hunan Cancer Hospital

Recruiting

Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer

Ovarian Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Metastatic Malignant Neoplasm in the Liver | Advanced Malignant Neoplasm | Refractory Malignant Neoplasm | Colorectal Carcinoma Metastatic in the Liver

United States
Cephalon, Inc.

Completed

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

Breast Cancer

Austria, Belgium, France, Germany, Italy, Spain
Oncotherapeutics
Takeda

Completed

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Multiple Myeloma

United States
Luye Pharma Group Ltd.

Completed

Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer

Advanced Breast Cancer

China
InxMed (Shanghai) Co., Ltd.

Active, not recruiting

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Locally Advanced or Metastatic Solid Tumors

China
M.D. Anderson Cancer Center
Spectrum Pharmaceuticals, Inc

Completed

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Leukemia

United States
Women's Hospital School Of Medicine Zhejiang University

Active, not recruiting

Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer

Efficacy and Safety

China
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States, Canada, Israel, Australia, Puerto Rico
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Bioequivalence

China
University of California, San Francisco
Washington University School of Medicine; Eisai Inc.

Terminated

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Peripheral T-Cell Lymphoma

United States
Sun Yat-sen University

Unknown

DCV in the Treatment of Recurrence and Refractory Childhood Solid Tumors

Unrecognized Condition
Ayana Pharma Ltd.,
Lambda Therapeutic Research Ltd.

Completed

A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.

Ovarian Cancer Recurrent

India
Tianjin Medical University Second Hospital
CSPC Pharmaceutical Group Limited

Unknown

Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Muscle Invasive Bladder Cancer

China
Jilin University

Unknown

Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy

Antineoplastic Combined Chemotherapy Protocols

China
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

Recurrent Childhood Acute Lymphoblastic Leukemia

United States, Australia, Canada, Puerto Rico
National Cancer Institute (NCI)

Completed

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood... and other conditions

United States, Canada, Australia, Puerto Rico
Hebei Medical University Fourth Hospital

Completed

A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer

Breast Cancer

China
Beijing Friendship Hospital

Unknown

L-DEP as an Initial Treatment for EBV-HLH

Hemophagocytic Lymphohistiocytosis

China
Dr. Reddy's Laboratories Limited

Completed

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Ovarian Epithelial Cancer Recurrent

India
Hebei Medical University Fourth Hospital

Unknown

Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer

Breast Cancer

China
National Cancer Institute (NCI)

Terminated

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Unspecified Childhood Solid Tumor, Protocol Specific | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Childhood Chronic Myelogenous Leukemia | Cutaneous B-cell Non-Hodgkin Lymphoma | Hepatosplenic T-cell Lymphoma | Intraocular Lymphoma | Recurrent Childhood Acute Lymphoblastic... and other conditions

United States, Canada
Northwestern University
National Cancer Institute (NCI)

Completed

Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer

Breast Cancer

United States
Janssen Pharmaceutical K.K.

Completed

A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Telik

Completed

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Ovarian Neoplasms

United States, Czech Republic, South Africa, Argentina, Belgium, Spain, Brazil, Chile, Germany, Hungary, Ireland, Netherlands, United Kingdom
University of Chile

Completed

Local Anesthetic Properties of Neosaxitoxin

Healthy Volunteers

Chile
First Affiliated Hospital of Zhejiang University
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Recruiting

Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML

Myeloid Malignancy | Relapsed/Refractory Acute Myeloid Leukaemia

China
Roswell Park Cancer Institute

Not yet recruiting

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Unresectable Triple-Negative Breast Carcinoma

United States
Ba Yi
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

Biliary Tract Carcinoma

China
Sun Yat-sen University

Recruiting

Liposomal Bupivacaine vs Ropivacaine for TAPBs

Postoperative Analgesia | Ropivacaine | Liposomal Bupivacaine | Abdominal Tumor

China
Peking Union Medical College Hospital

Not yet recruiting

Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients (MA-PC-RWS-011)

Pancreatic Cancer

China
Peking University People's Hospital
Peking University Shougang Hospital; Shandong Cancer Hospital and Institute

Recruiting

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Ewing Sarcoma

China
Tianjin Medical University Cancer Institute and...
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer

Metastatic Biliary Tract Cancer

China
HRYZ Biotech Co.

Not yet recruiting

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Leiomyosarcoma | Fibrosarcoma | Liposarcoma | Angiosarcoma | Synovial Sarcoma | Endometrial Stromal Sarcoma | Undifferentiated Pleomorphic Sarcoma | Epithelioid Sarcoma | Desmoplastic Small Round Cell Tumor | Malignant Peripheral Nerve Sheath Tumors | Pleomorphic Rhabdomyosarcoma

China
Fudan University

Not yet recruiting

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Small Cell Lung Cancer Recurrent

China
Children's Hospital of Soochow University

Recruiting

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML (GMCAII)

Acute Myeloid Leukemia | AML, Childhood

China
Wuhan Union Hospital, China
CSPC Pharmaceutical Group Limited

Recruiting

Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies

B-cell Acute Lymphoblastic Leukemia | B-cell Lymphoma Refractory

China
National Research Center for Hematology, Russia

Recruiting

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Primary Mediastinal Lymphoma

Russian Federation
Luye Pharma Group Ltd.

Recruiting

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

Relapsed Small Cell Lung Cancer

China
University of Rochester

Not yet recruiting

Reducing Frailty for Older Cancer Survivors Using Supplements II (ReFOCUS2)

Inflammation | Frailty

United States

Search clinical trials for: Doxorubicin Hydrochloride Liposome Injection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations